Amedisys (NASDAQ:AMED) has been given a $150.00 target price by equities research analysts at Jefferies Financial Group in a research report issued to clients and investors on Monday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the health services provider’s stock. Jefferies Financial Group’s price objective points to a potential upside of 24.40% from the stock’s current price.
AMED has been the subject of several other reports. ValuEngine upgraded Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, June 22nd. BidaskClub upgraded Amedisys from a “sell” rating to a “hold” rating in a research note on Wednesday, June 5th. Raymond James upgraded Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 target price for the company in a research note on Thursday, May 2nd. Finally, Barclays upped their target price on Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, March 21st. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $131.43.
NASDAQ AMED opened at $120.58 on Monday. Amedisys has a fifty-two week low of $91.77 and a fifty-two week high of $140.91. The firm has a market capitalization of $3.91 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 1.51 and a beta of 1.35. The business has a fifty day moving average of $117.04. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91.
In other Amedisys news, insider David L. Kemmerly sold 5,000 shares of the business’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $109.96, for a total transaction of $549,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott G. Ginn sold 4,872 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $118.50, for a total value of $577,332.00. The disclosure for this sale can be found here. Insiders sold 45,028 shares of company stock valued at $5,210,707 over the last quarter. Insiders own 2.90% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Alpha Quant Advisors LLC lifted its stake in shares of Amedisys by 137.0% in the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after acquiring an additional 137 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of Amedisys by 161.8% in the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after acquiring an additional 369 shares in the last quarter. Meeder Asset Management Inc. lifted its stake in shares of Amedisys by 102.3% in the first quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock worth $120,000 after acquiring an additional 488 shares in the last quarter. National Asset Management Inc. acquired a new position in shares of Amedisys in the first quarter worth about $211,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Amedisys in the first quarter worth about $213,000. 86.30% of the stock is owned by hedge funds and other institutional investors.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.